Lung Cancer

The PD-1 inhibitor cemiplimab significantly improved overall survival as a frontline treatment for patients with high–PD-L1 non–small cell lung cancer.

The National Medical Products Administration of China has accepted an application for the PD-1 inhibitor sintilimab injection for use in combination with pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with nonsquamous non–small cell lung cancer.

The China National Medical Products Administration has accepted a supplemental new drug application for the PD-1 inhibitor tislelizumab for use in combination with chemotherapy for the first-line treatment of patients with advanced squamous non–small cell lung cancer.

Nivolumab combined with ipilimumab significantly improved overall survival versus chemotherapy in previously untreated patients with malignant pleural mesothelioma.

Join oncologists nationwide who have learned from the top leaders in the lung cancer field as they share their insights on coronavirus disease 2019 and how the pandemic is poised to have a significant impact on lung cancer treatment and the health care system. Join us Thursday, May 28, 2020 at 8 PM EST.

The PD-1 inhibitor tislelizumab combined with frontline chemotherapy significantly improved progression-free survival versus chemotherapy alone in patients with nonsquamous non–small cell lung cancer.